WP
TBPH icon

Woodline Partners’s Theravance Biopharma TBPH Stock Holding History

Woodline Partners’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$489K Buy
+30,122
New +$533K ﹤0.01% 970
2022
Q4 		– Sell
-119,854
Closed -$1.22M – 841
2022
Q3 		$1.22M Sell
119,854
-2,123,619
-95% -$19.9M 0.02% 522
2022
Q2 		$20.3M Buy
2,243,473
+916,820
+69% +$8.45M 0.31% 97
2022
Q1 		$12.7M Buy
1,326,653
+751,540
+131% +$7.36M 0.21% 151
2021
Q4 		$6.36M Sell
575,113
-1,404,017
-71% -$12.2M 0.09% 256
2021
Q3 		$14.6M Buy
1,979,130
+1,604,218
+428% +$17.9M 0.24% 117
2021
Q2 		$5.44M Buy
+374,912
New +$7.04M 0.1% 209

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners's TBPH Position: Q1 2026 in Review

Woodline Partners opened a new position in Theravance Biopharma (TBPH) in Q1 2026: 30,122 shares worth $489K. The stake represents ﹤0.01% of the portfolio and ranks #970 among its holdings. This is a return to the name: Woodline Partners previously reported a position in TBPH as recently as Q3 2022.

Woodline Partners first reported a position in TBPH in Q2 2021 and has held it in 7 quarters since. The position peaked at $20.3M in Q2 2022. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • Woodline Partners held 30,122 shares of Theravance Biopharma worth $489K as of Q1 2026.
  • Theravance Biopharma was a new Woodline Partners position in Q1 2026.
  • Theravance Biopharma made up ﹤0.01% of Woodline Partners's portfolio in Q1 2026, its #970 holding.
  • Woodline Partners first reported a position in Theravance Biopharma in Q2 2021 and has held it in 7 quarters since.
  • Woodline Partners's Theravance Biopharma position peaked at $20.3M in Q2 2022.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.